128 related articles for article (PubMed ID: 1747725)
1. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
Hoeltl W; Hasun R; Albrecht W; Marberger M
Br J Urol; 1991 Nov; 68(5):495-8. PubMed ID: 1747725
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized trial to evaluate high-versus low-dose interferon-alpha 2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder.
Hoeltl W; Hasun R; Albrecht W
Anticancer Drugs; 1992 May; 3 Suppl 1():29-32. PubMed ID: 1611114
[TBL] [Abstract][Full Text] [Related]
3. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Raitanen MP; Lukkarinen O
Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
[TBL] [Abstract][Full Text] [Related]
5. [Clinical trial with intravesical alfa-2b interferon for the prevention of T1 transitional carcinoma of the bladder: preliminary results. Review of the bibliography].
Portillo Martín JA; Martín García B; Hernández Rodríguez R; Correas Gómez MA; Gutiérrez Baños JL; del Valle Schaan JI; Monge Mirallas JM; Roca Edreira A
Arch Esp Urol; 1995 Jun; 48(5):479-88. PubMed ID: 7639570
[TBL] [Abstract][Full Text] [Related]
6. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.
Portillo J; Martin B; Hernandez R; Correas M; Gutierrez J; Del Valle J; Roca A; Vega A; Villanueva A; Gutierrez R
Urology; 1997 Feb; 49(2):187-90. PubMed ID: 9037279
[TBL] [Abstract][Full Text] [Related]
7. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
Flamm J; Bucher A; Höltl W; Albrecht W
J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
[TBL] [Abstract][Full Text] [Related]
8. Role of interferon-alpha-2b in the prevention of superficial carcinoma of the bladder recurrence.
Mohanty NK; Gulati P; Saxena S
Urol Int; 1997; 59(3):194-6. PubMed ID: 9428441
[TBL] [Abstract][Full Text] [Related]
9. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
11. [Immunoprophylaxis of recurrence of T1 G2 bladder tumors with interferon alpha-2b].
Salinas Sánchez AS; Hernández Millán I; Pastor Guzmán JM; Martínez Martín M; Cañamares Pabolaza L; Virseda Rodríguez JA
Actas Urol Esp; 1993 Jul; 17(7):415-20. PubMed ID: 8368114
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
Flamm J; Bucher A
Br J Urol; 1991 Jan; 67(1):70-3. PubMed ID: 1993279
[TBL] [Abstract][Full Text] [Related]
13. Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors.
Kostakopoulos A; Deliveliotis C; Mavromanolakis E; Aravantinos G; Dimopoulos MA
Eur Urol; 1990; 18(3):201-3. PubMed ID: 2261932
[TBL] [Abstract][Full Text] [Related]
14. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
15. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
[TBL] [Abstract][Full Text] [Related]
16. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
[TBL] [Abstract][Full Text] [Related]
18. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder.
Bazarbashi S; Soudy H; Abdelsalam M; Al-Jubran A; Akhtar S; Memon M; Aslam M; Kattan S; Shoukri M
BJU Int; 2011 Oct; 108(7):1115-8. PubMed ID: 21332904
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.
Ferrari P; Castagnetti G; Pollastri CA; Ferrari G; Tavoni F; Grassi D
Anticancer Drugs; 1992 May; 3 Suppl 1():25-7. PubMed ID: 1611113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
